What if cancer treatment could harness the body’s own immune system instead of relying on surgery, radiation, or chemotherapy? GT Biopharma (NASDAQ: GTBP) is developing its TriKE® platform, a novel NK cell engager designed to activate natural killer cells to seek out and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company’s origins, the science behind its technology, and its progress in clinical trials for acute myeloid leukemia. He also outlines GT Biopharma’s plans to expand into solid tumors and autoimmune diseases, highlighting the commercial potential and challenges ahead. Watch the full interview to learn how the company is advancing immunotherapy in a new direction. Learn more about GT Biopharma: https://www.gtbiopharma.com/ Watch the full YouTube interview here: https://youtu.be/Z9tNa4JTELw And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
